No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3056-3060

  Bernards, N ^a,b   Creemers, G J ^b   Nieuwenhuijzen, G A P ^b   Bosscha, K ^c   Pruijt, J F M ^c   Lemmens, V E P P ^a,d  

^a Eindhoven Cancer Registry   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Gastric cancer; Hospital variation; Metastasis; Survival

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENDER; HUMAN; LINITIS PLASTICA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERITONEUM METASTASIS; POPULATION RESEARCH; PRIORITY JOURNAL; SOCIAL STATUS; STOMACH CANCER; SURVIVAL RATE;

CHEMOTHERAPY; GASTRIC CANCER; HOSPITAL VARIATION; METASTASIS; SURVIVAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84888780224     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt401     Document Type: Article

References (26)

1. Murad AM, Santiago FF, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
2. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585-1595.
3. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010 Mar 17; (3): CD004064.
4. Landelijke werkgroep Gastro-Intestinale Tumoren. Dutch guideline: gastric carcinoma, 2009.
5. National Comprehensive Cancer Network. NCCN Guideline Gastric Cancer, 2012.
6. Okines A, Verheij M, Allum W et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v50-v54.
7. Ho VK, Damhuis RA, Hartgrink HH. Adherence to national guidelines for gastric cancer in the netherlands: A retrospective population-based audit. Int J Cancer 2013; 132: 1156-1161.
8. Aarts MJ, van der Aa MA, Coebergh JW et al. Reduction of socioeconomic inequality in cancer incidence in the South of the Netherlands during 1996-2008. Eur J Cancer 2010; 46: 2633-2646.
9. Dassen AE, Lips DJ, Hoekstra CJ et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009; 35: 449-455.
10. Hopkins S, Yang GY. FDG PET imaging in the staging and management of gastric cancer. J Gastrointest Oncol 2011; 2: 39-44.
11. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
12. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
13. van Gils CW, Koopman M, Mol L et al. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands. Acta Oncol 2012; 51: 57-64.
14. Hershman DL, Buono D, McBride RB et al. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 2009; 115: 3848-3857.
15. Aarts MJ, Hamelinck VC, Bastiaannet E et al. Small but significant socioeconomic inequalities in axillary staging and treatment of breast cancer in the Netherlands. Br J Cancer 2012; 107: 12-17.
16. Aarts MJ, Koldewijn EL, Poortmans PM et al. The impact of socioeconomic status on prostate cancer treatment and survival in the Southern Netherlands. Urology 2013; 81: 593-599.
17. Bus P, Aarts MJ, Lemmens VE et al. The effect of socioeconomic status on staging and treatment decisions in esophageal cancer. J Clin Gastroenterol 2012; 46: 833-839.
18. Randen M, Helde-Frankling M, Runesdotter S et al. Treatment decisions and discontinuation of palliative chemotherapy near the end-of-life, in relation to socioeconomic variables. Acta Oncol 2013; 52: 1062-1066.
19. Kao S, Shafiq J, Vardy J et al. Use of chemotherapy at end of life in oncology patients. Ann Oncol 2009; 20: 1555-1559.
20. Schildmann J, Tan J, Salloch S et al. "Well, I think there is great variation.": a qualitative study of oncologists' experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer. Oncologist 2013; 18: 90-96.
21. Lu Z, Lu M, Zhang X et al. Advanced or metastatic gastric cancer in elderly patients: clinicopathological, prognostic factors and treatments. Clin Transl Oncol 2013; 15: 376-383.
22. Syrios J, Sougioultzis S, Xynos ID et al. Survival in patients with stage IV noncardia gastric cancer-the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer 2012; 12: 264.
23. Gan L, He J, Zhang X et al. Expression profile and prognostic role of sex hormone receptors in gastric cancer. BMC Cancer 2012; 12: 566.
24. Yang D, Hendifar A, Lenz C et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol 2011; 2: 77-84.
25. Lee J, Lim T, Uhm JE et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007; 18: 886-891.
26. Shridhar R, Almhanna K, Hoffe SE et al. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: A surveillance, epidemiology, and End results database analysis. Cancer 2013; 119: 1636-1642.